Sign in

    Elena Bidros • Lucid

    Elena Bidros is an Equity Analyst at Lucid, specializing in coverage of automotive and electric vehicle sectors with a focus on technology-driven companies such as Lucid Group Inc. She provides in-depth analysis of firms including NAS:LCID, leveraging performance metrics like ESG risk ratings and industry rankings for her investment research. Bidros began her analyst career in recent years and joined Lucid in 2023, contributing fresh insights to the team with her experience in ESG and sustainability assessments. She maintains relevant securities credentials and is recognized for her rigorous evaluations of company risk and performance based on global indices.

    Elena Bidros's questions to Vistagen Therapeutics Inc (VTGN) leadership

    Elena Bidros's questions to Vistagen Therapeutics Inc (VTGN) leadership • Q1 2026

    Question

    Elena Bidros from Lucid posed two questions: first, what efficacy or other measures are captured in the open-label extension study besides safety; and second, for Vistagen's opinion on the competing Phase III trial for social anxiety disorder being conducted by Neuphoria.

    Answer

    COO Joshua Prince explained that the open-label study measures the Leibowitz Social Anxiety Scale (LSAS) monthly to track long-term severity. CEO Shawn Singh added that they also monitor drug utilization patterns. Regarding the competitor, Singh highlighted Fasedienol's differentiated non-systemic, rapid-onset mechanism and first-mover advantage, while viewing the competitor's use of a similar public speaking challenge as validation of the clinical trial model.

    Ask Fintool Equity Research AI